HK Stock Market Move | UNITED LAB (03933) rose over 6% in morning trading as the marketing application for semaglutide injection for weight management indication was accepted

UNITED LAB (03933) rose over 6% in morning trading. As of press time, it was up 5.66% at HK$7.745, with a turnover of HK$24.1351 million. On the news front, UNITED LAB announced that the marketing registration application for the weight management indication of semaglutide injection submitted by its wholly-owned subsidiary Zhuhai United Laboratories Biopharmaceutical Co., Ltd. has been accepted by China's National Medical Products Administration. Semaglutide injection is mainly used for glycemic control in patients with type 2 diabetes, long-term weight management in patients with obesity or overweight, and reducing the risk of related adverse cardiovascular events. This marketing registration application for the weight management indication further enriches the product's indication layout and is expected to bring clinical benefits to a broader patient population. The company has built a differentiated product pipeline combining innovative drugs and biosimilars around the GLP-1 target to enhance its market competitiveness in the biopharmaceutical field. In the future, the company will continue to be committed to the research and development of new products, which is expected to create greater returns for the company and its shareholders.